Arrhythmias & electrophysiologyCohort study
Heart failure in patients with recently diagnosed atrial fibrillation: findings from the GLORIA-AF Registry Phase III
- Prospective registry cohort study
Authors' conclusion
Congestive heart failure is common in real-world patients with AF and is associated with a more complex clinical phenotype, different management, and worse prognosis.
Study context
- Population
- Adults with recently diagnosed atrial fibrillation (AF) and CHA2DS2-VASc ≥ 1 (GLORIA-AF Registry Phase III)
- Participants
- 21,125 adults
- Exposure
- Congestive heart failure (CHF) vs no CHF in AF
- CHFn = 4,632
- Outcome
- Composite of:
- All-cause death
- Major adverse cardiovascular events (MACE)
- Follow-up
- 3-year follow-up
Main finding
All-cause death and MACE
Hazard ratio
2.04
95% CI 1.87–2.23
CHF vs No CHF
HR 2.04 (95% CI 1.87–2.23)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | OR (95% CI) | |
|---|---|---|
| OAC prescription, CHF with LVEF ≤ 40% | 1.47 (1.27–1.71) | |
| 0.512Odds ratio (log scale) |
Oral anticoagulants (OAC) prescription, CHF with left ventricular ejection fraction (LVEF) ≤ 40%
- No significant differences for CHF with LVEF > 40%
NOAC vs VKA use
- NOACs less used than VKA in CHF, irrespective of LVEF
Secondary outcomes incl. thromboembolism
- Similar results (increased risk with CHF); higher risk increases with LVEF ≤ 40%
Original publication
Heart failure in patients with recently diagnosed atrial fibrillation: findings from the GLORIA-AF Registry Phase III. Eur J Prev Cardiol. Published 1 September 2025. doi:10.1093/eurjpc/zwaf485
Summarised from the published abstract; every number is checked against it